ReviewCurrent neuropharmacology2015
Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.
Review in Current neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Lorazepam in Managing Atypical Neuroleptic Malignant Syndrome: A Systematic Review of Case Reports.The western journal of emergency medicine · 2025Pooled it
- The use of antipsychotics in the treatment of catatonia: a systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar disorders · 2018Guideline
- Acute Febrile Encephalopathy with Rigidity.Journal of intensive care medicine · 2026Review
- Molecular Mechanisms of Acute Drug Toxicity in Polypharmacy: Analgesic-Psychotropic Interactions.International journal of molecular sciences · 2026Review
- Atypical neuroleptic malignant syndrome without hyperthermia or rigidity in the ıntensive care unit: a diagnostic challenge.Acta neurologica Belgica · 2026Article
- Co-occurrence of Neuroleptic Malignant Syndrome and Silent Syndrome in a Patient With Bipolar Disorder: Clinical Challenges and Long-term Neurological Sequelae.Cerebellum (London, England) · 2026Article
- Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.Brain : a journal of neurology · 2026Review
- Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects.Clinical parkinsonism & related disorders · 2026Review
- Promethazine-induced neuroleptic malignant syndrome under general anesthesia: a case report.Frontiers in psychiatry · 2026Article
- Clinical Outcomes and Factors Associated with Neuroleptic Malignant Syndrome in Older Patients: A Case Control Study.Journal of clinical medicine · 2025Article
- Systematic analysis of adverse reactions associated with dantrolene treatment: From clinical features to molecular mechanisms.Medicine · 2025Article
- Neuroleptic Malignant Syndrome on Chronic Trifluoperazine Therapy: A Diagnostic Dilemma.Clinical case reports · 2025Article
- Successful treatment of five cases of catatonia treated with guanfacine without ECT: a case series from a psychiatric hospital in Japan.BMC psychiatry · 2025Article
- Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol.Clinical case reports · 2025Article
- Neuroleptic malignant syndrome in a patient with COVID-19 and the possible role of SARS-CoV-2 in its manifestation: case report and overview of published cases.BMC psychiatry · 2025Review
- Conceptualizing the relationship between synthetic cannabinoid use and neuroleptic malignant syndrome.Bipolar disorders · 2025Article
- Neuroleptic Malignant Syndrome with Low-dose Quetiapine After Venlafaxine Withdrawal: A Case Report.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2025Article
- Neuroleptic malignant syndrome in Huntington disease.European journal of neurology · 2024Article
- Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study.Journal of child and adolescent psychopharmacology · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening side-effect that can occur in response to treatment with antipsychotic drugs. Symptoms commonly include hyperpyrexia, muscle rigidity, autonomic dysfunction and altered mental status. In the current review we provide an overview on past and current developments in understanding the causes and treatment of NMS. Studies on the epidemiological incidence of NMS are evaluated, and we provide new data from the Canada Vigilance Adverse Reaction Online database to elaborate on drug-specific and antipsychotic drug polypharmacy instances of NMS reported between 1965 and 2012. Established risk factors are summarized with an emphasis on pharmacological and environmental causes. Leading theories about the etiopathology of NMS are discussed, including the potential contribution of the impact of dopamine receptor blockade and musculoskeletal fiber toxicity. A clinical perspective is provided whereby the clinical presentation and phenomenology of NMS is detailed, while the diagnosis of NMS and its differential is expounded. Current therapeutic strategies are outlined and the role for both pharmacological and non-pharmacological treatment strategies in alleviating the symptoms of NMS are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.